# A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Source: https://onco.cc/trials/nct06095089/  
OnCo record `nct06095089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of HLD-0915 (JNJ-101556143) run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer is a phase 1 interventional study registered as NCT06095089 by Janssen Research & Development, LLC, with 355 participants planned, started 2023-11-01. Conditions recorded: Prostatic Neoplasms. Interventions recorded: JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan and JNJ-101556143.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06095089
- Phase: 1
- Setting: A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 355

## Sources

- ClinicalTrials.gov NCT06095089: https://clinicaltrials.gov/study/NCT06095089

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [HLD-0915 (JNJ-101556143)](https://onco.cc/drugs/hld-0915/)
- companies: [Halda Therapeutics](https://onco.cc/companies/halda-therapeutics/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06095089.json